Arbutus wins claim construction ruling in patent suit vs Pfizer/BioNTech over COVID-19 vaccine LNP technology

Arbutus Biopharma Corp

Court adopted Arbutus's proposed construction for 'fully encapsulated' as 'contained inside' in five LNP patents.
Court rejected Pfizer/BioNTech's proposal and declined to add 'as distinct from partially' used in prior Moderna ruling.
Patent claims cover lipid nanoparticle compositions used in COMIRNATY COVID-19 vaccine; damages sought.
Ruling narrows scope of disputed terms, strengthening Arbutus's infringement case; trial on merits pending.
Arbutus and licensee Genevant Sciences assert five patents against Pfizer/BioNTech in New Jersey action.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.